Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.60 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.60 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 4/20 | 0.59 |
| ▸ | LYN | P07948 | 1/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
| ▸ | ITK | Q08881 | 2/20 | 0.54 |
| ▸ | VHL | P40337 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31100602 | 0.91 | BTK (0.60) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31103403 | 0.90 | BTK (0.61) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31102837 | 0.89 | BTK (0.59) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31102912 | 0.89 | BTK (0.56) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31100875 | 0.89 | BTK (0.57) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31102460 | 0.88 | BTK (0.59) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31101916 | 0.88 | BTK (0.56) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31100258 | 0.88 | BTK (0.58) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31103192 | 0.88 | BTK (0.61) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL31101820 | 0.87 | BTK (0.61) | BTKNUDT14NUDT5LCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| WO-2024188209-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-09-19 | — | — | WO | claimed |